Novartis AG (STU:NOTA) Current Deferred Taxes Liabilities: € Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:NOTA Novartis AG STU:NOTA
78 GF Score
Price €123.00
GF Value €112.42
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Novartis AG Current Deferred Taxes Liabilities?

Novartis AG STU:NOTA 78 Current Deferred Taxes Liabilities is € Mil as of Jun. 2026. GuruFocus rates STU:NOTA with a GF Score™ of 78/100 and a GF Value™ of €112.42 (Fairly Valued). The stock has 2 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Novartis AG's current deferred tax liabilities for the quarter that ended in Jun. 2026 was € Mil.

Novartis AG Current Deferred Taxes Liabilities Related Terms

Novartis AG Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Novartis AG's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG Current Deferred Taxes Liabilities Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Novartis AG Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
STU:NOTA
78GF Score
Novartis AG STU:NOTA
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of € Mil mean?
Novartis AG (STU:NOTA) has a Current Deferred Taxes Liabilities of € Mil as of Jun. 2026. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Novartis AG and its competitors.
Is Novartis AG's Current Deferred Taxes Liabilities too high?
Novartis AG's current Current Deferred Taxes Liabilities is € Mil. Overall, Novartis AG has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Current Deferred Taxes Liabilities compare to LLY and JNJ?
Novartis AG's Current Deferred Taxes Liabilities of € Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Drug Manufacturers company?
A good Current Deferred Taxes Liabilities depends on the Drug Manufacturers industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Novartis AG and its competitors. Novartis AG's current Current Deferred Taxes Liabilities is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (STU:NOTA) is currently considered Fairly Valued. The stock's GF Value™ is €112.42, compared to a current price of €123.00 — trading 9.4% above its estimated fair value. The current Current Deferred Taxes Liabilities is € Mil. Novartis AG's overall GF Score™ is 78/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Novartis AG (STU:NOTA), the current Current Deferred Taxes Liabilities is € Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (STU:NOTA) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €123.00 is trading 9.4% above its estimated GF Value™ of €112.42. GuruFocus considers Novartis AG to be Fairly Valued.

Key valuation signals for STU:NOTA:

  • Current Deferred Taxes Liabilities: € Mil
  • GF Value™: €112.42 vs. price of €123.00 (9.4% above fair value)
  • GF Score™: 78/100 with 2 warning signs

No single metric tells the full story. See the STU:NOTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis is a Swiss global pharmaceutical company focused exclusively on innovative prescription medicines after spinning off its Sandoz generics business in 2023. Key therapeutic areas include cardiovascular disease, led by cholesterol-lowering Leqvio and heart-failure treatment Entresto; oncology, including breast cancer therapy Kisqali, radioligand therapy Pluvicto, and Scemblix for leukemia; immunology, with psoriasis and arthritis biologic Cosentyx; and neuroscience and rare diseases, including multiple sclerosis therapy Kesimpta and gene therapy Zolgensma. Novartis pioneered CAR-T cell therapy (Kymriah) and radioligand therapeutics, and maintains a large development pipeline across small molecules, biologics, gene and cell therapies. Headquartered in Basel, Switzerland, it sells medicines in most countries worldwide, with the United States its largest market. Its ADRs trade on the NYSE.
78GF Score

Get the complete analysis for STU:NOTA

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€123.00
Price
€112.42
GF Value